OXFORD - Britain's second big life sciences merger could signal anxious times ahead for many companies worried about their fate if a widely anticipated shakeout hits the U.K. biotech sector.

The new fear is that the creation of large cap profitable integrated life science companies will create giants of such critical mass that they will develop a gravitational pull attracting all investor attention, and orphaning the rest of the sector in their wake.